Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005611-46
    Sponsor's Protocol Code Number:TAVT45C02
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-07-06
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-005611-46
    A.3Full title of the trial
    Phase 3 study investigating the efficacy and safety of TAVT-45 (abiraterone acetate) Granules for Oral Suspension (a novel abiraterone acetate formulation) relative to a reference abiraterone acetate formulation in patients with metastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC).
    Estudio de fase III que investiga la eficacia y la seguridad de los granulados de TAVT-45 (acetato de abiraterona) para suspensión oral (una nueva formulación de acetato de abiraterona) en relación con una formulación de acetato de abiraterona de referencia en pacientes con cáncer de próstata sensible a la castración metastásico (CPSCm) y cáncer de próstata resistente a la castración metastásico (CPRCm)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 3 study to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer
    Estudio de fase 3 para investigar la seguridad y eficacia de una nueva formulación de un medicamento existente llamado TAVT-45 en pacientes con cáncer de próstata metastásico
    A.4.1Sponsor's protocol code numberTAVT45C02
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorTavanta Therapeutics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTavanta Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationTavanta Therapeutics, Inc.
    B.5.2Functional name of contact pointRegulatory Affairs
    B.5.3 Address:
    B.5.3.1Street Address101 E. Baltimore Ave, # 602
    B.5.3.2Town/ cityMedia, PA
    B.5.3.3Post code19063
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1833776 8963
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTAVT-45
    D.3.4Pharmaceutical form Granules for oral suspension in sachet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNABIRATERONE ACETATE
    D.3.9.1CAS number 154229-18-2
    D.3.9.2Current sponsor codeTAVT-45
    D.3.9.3Other descriptive nameABIRATERONE ACETATE
    D.3.9.4EV Substance CodeSUB31647
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Zytiga
    D.2.1.1.2Name of the Marketing Authorisation holderJanssen-Cilag International N.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameZytiga
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNABIRATERONE ACETATE (Zytiga)
    D.3.9.1CAS number 154229-18-2
    D.3.9.2Current sponsor coden/a
    D.3.9.3Other descriptive nameABIRATERONE ACETATE
    D.3.9.4EV Substance CodeSUB31647
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrednisone
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPREDNISOLONE
    D.3.9.1CAS number 50-24-8
    D.3.9.2Current sponsor coden/a
    D.3.9.3Other descriptive namePrednisone
    D.3.9.4EV Substance CodeSUB10018MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrednisone
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPREDNISOLONE
    D.3.9.1CAS number 50-24-8
    D.3.9.2Current sponsor coden/a
    D.3.9.3Other descriptive namePrednisone
    D.3.9.4EV Substance CodeSUB10018MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic
    Castrate Resistant Prostate Cancer (mCRPC)
    Cáncer de próstata metastásico sensible a la castración (mCSPC) y cáncer de próstata metastásico resistente a la castración (mCRPC)
    E.1.1.1Medical condition in easily understood language
    Prostate Cancer
    Cáncer de próstata
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10036909
    E.1.2Term Prostate cancer metastatic
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10060862
    E.1.2Term Prostate cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10076506
    E.1.2Term Castration-resistant prostate cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Establish equivalence between TAVT-45 granules and Zytiga tablets in patients with metastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC).
    Establecer la equivalencia terapéutica entre los granulados de TAVT-45 y los comprimidos de Zytiga® en pacientes con cáncer de próstata sensible a la castración metastásico (CPSCm) y cáncer de próstata resistente a la castración metastásico (CPRCm)
    E.2.2Secondary objectives of the trial
    Characterize the multiple-dose pharmacokinetic profile of TAVT-45 in a cohort of patients.
    Describir el perfil farmacocinético de múltiples dosis de TAVT-45 en una cohorte de pacientes.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Written informed consent obtained prior to any study-related procedure being performed
    2. Male patients at least 18 years of age or older at time of consent
    3. Pathologically confirmed adenocarcinoma of the prostate
    4. Ongoing therapy with a gonadotropin releasing hormone (GnRH) agonist or antagonist (unless patient has already had a bilateral orchiectomy) AND serum testosterone level <50 ng/dL at screening
    5. Have either metastatic CSPC or metastatic CRPC, as defined below:
    a). CSPC: Using the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) system, patients must have Tany Nany M+ (distant metastases) disease AND two of the following:
    -Gleason score of 8 or greater
    -Three or more bone scan lesions
    -Measurable visceral metastases
    b). CRPC: Patients must have metastatic* disease, and must also have disease progression according to the recommendations of the Prostate Cancer Working Group 3 by having at least one of the following criteria:
    -Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of at least 1 ng/mL
    -Imaging progression (CT/MRI) by RECIST 1.1 criteria or PET/CT*
    -Nuclear scan progression by 2 or more new bone lesions.
    *Note: Metastatic disease should be documented by MRI/CT, PET/CT (including, but not limited to, standard of care imaging using 18F-fluciclovine, 11C-choline, or PSMA where approved) or bone scan. Imaging obtained within 90 days prior to the start of study drug/reference product will be accepted.
    6. The following prior treatment and or surgery for prostate cancer are allowed:
    a) CSPC:
    i) Up to 90 days of androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists/antagonists or orchiectomy with or without concurrent anti-androgens prior to patients' randomization is permitted
    ii) Patients may have one course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease (e.g., impending cord compression or obstructive symptoms) if administered prior to randomization
    iii) Radiation or surgical therapy that was not initiated 4 weeks after the start of ADT or orchiectomy
    b) CRPC:
    i). Previous chemotherapy with docetaxel for metastatic disease with treatment completed at least 1 year prior to enrolment
    7. Discontinuation of flutamide or nilutamide, and other anti-androgens prior to the start of study medication; discontinuation of bicalutamide prior to start of study medication
    8. Discontinuation of strong CYP3A4 inducers at prior to start of study medication
    9. Discontinuation of radiotherapy prior to start of study medication
    10. Discontinuation of supplements (herbal and mineral) 30 days prior to the first dose of study medication and for the duration of the trial. Use of a basic multi-vitamin is allowed.
    11. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at screening
    12. Normal organ function with acceptable initial laboratory values within the screening period:
    ANC: ≥ 1,500/µl
    Albumin: ≥ 3.0g/dL
    Hemoglobin: ≥ 9g/dL
    Platelet count: ≥ 100,000/µl
    Serum Creatinine: ≤ 3.0 x the institutional upper limit of normal (ULN)
    Potassium: ≥ 3.5 mmol/L (within institutional normal range)
    Bilirubin: ≤ 1.5 ULN (unless documented Gilbert's disease)
    SGOT (AST): ≤ 2.5 x ULN
    SGPT (ALT): ≤ 2.5 x ULN
    13. Life expectancy of at least 6 months at screening
    14. Patients engaged in sex with women of child-bearing potential agree to use a condom plus another effective contraception method. Patients agree to use a condom when engaged in any sexual activity, including sex with a pregnant woman. These restrictions will apply from the time informed consent is provided until 3 weeks after the last dose of study medication is taken.
    15. Patient is willing and able to comply with all protocol requirements assessments
    1. Que se haya obtenido el consentimiento informado por escrito antes de cualquier procedimiento relacionado con el estudio
    2. Pacientes varones de al menos 18 años en el momento del consentimiento
    3. Adenocarcinoma de la próstata confirmado patológicamente
    4. Tratamiento en curso con el agonista o antagonista de la hormona liberadora de gonadotropinas (Gn-RH) (a menos que el paciente ya se haya sometido a una orquiectomía bilateral) Y que el nivel de testosterona en suero sea < 50 ng/dl en la selección
    5. Que padezca CPSC metastásico o CPRC metastásico, según se define a continuación:
    • CPSC: Según el sistema TNM (tumor-nódulo-metástasis) del Comité Conjunto Estadounidense sobre el Cáncer (AJCC, por sus siglas en inglés), los pacientes deben padecer una enfermedad en estadio T0N0M+ (metástasis distantes) Y dos de los siguientes:
    • Puntuación Gleason de 8 o superior
    • Tres o más lesiones según gammagrafías óseas
    • Metástasis viscerales cuantificables
    • CPRC: Los pacientes deberán tener una enfermedad metastásica* y la enfermedad deberá haber progresado de acuerdo con las recomendaciones del Grupo de trabajo sobre el cáncer de próstata 3 al cumplir al menos uno de los siguientes criterios:
    • Dos aumentos del PSA (obtenido con una separación mínima de 1 semana) desde la medición inicial de al menos 1 ng/ml
    • Progresión según escáneres (TAC/RM) según los criterios RECIST 1.1 o PET/TAC*
    • Progresión según escáner nuclear por 2 o más lesiones óseas nuevas
    *Nota: La enfermedad metastásica deberá documentarse mediante TAC/RM, PET/TAC (incluidos,
    entre otros, los escáneres del tratamiento habitual mediante 18F-Fluciclovina, 11C-Colina o PSMA cuando haya autorización) o gammagrafía ósea. Se aceptarán los escáneres obtenidos en los 90 días previos al inicio del medicamento del estudio/medicamento de referencia.
    6. Están permitidos los siguientes tratamientos o cirugías previos para el cáncer de próstata:
    • CPSC:
    • Se permiten hasta 90 días de tratamiento de privación androgénica (TPA) con agonistas/antagonistas de la hormona liberadora de gonadotropinas (Gn-RH) u orquiectomía con o sin antiandrógenos simultáneos antes de la aleatorización de los pacientes
    • Los pacientes pueden haber recibido un ciclo de radiación paliativa o un tratamiento quirúrgico para tratar los síntomas derivados de la enfermedad metastásica (p. ej., compresión de la médula espinal inminente o síntomas obstructivos) si se han administrado antes de la aleatorización
    • Radiación o tratamiento quirúrgico que no se iniciara 4 semanas después del inicio del TPA o la orquiectomía
    • CPRC:
    • Quimioterapia previa con docetaxel para la enfermedad metastásica con tratamiento completado al menos 1 año antes de la selección
    7. Interrupción de la flutamida o nilutamida, así como otros antiandrógenos antes del inicio del medicamento del estudio; interrupción de la bicalutamida antes del inicio del medicamento del estudio.
    8. Interrupción de los inductores potentes del CYP3A4 al menos 4 semanas antes del inicio del medicamento del estudio.
    9. Interrupción de la radioterapia antes del inicio del medicamento del estudio.
    10. Interrupción de todos los suplementos (herbarios y minerales) 30 días antes de la primera dosis del medicamento del estudio y durante todo el ensayo. Se permite el uso de multivitamínicos básicos.
    11. Estado funcional de 0-2 en la selección según el Grupo Oncológico Cooperativo de la Costa Este (ECOG)
    12. Función normal del órgano con valores analíticos iniciales aceptables durante el periodo de selección:
    CAN ≥ 1500/µl
    Albúmina > 3,0 g/dl
    Hemoglobina ≥ 9 g/dl
    Recuento plaquetario ≥100 000/µl
    Creatinina sérica ≤ 3 veces el límite superior de la normalidad (LSN) del centro Potasio > 3,5 mmoles/l (dentro del rango normal del centro)
    Bilirrubina ≤1,5 veces el LSN (a menos que se documente enfermedad de Gilbert)
    SGOT (AST) ≤ 2,5 veces el LSN
    SGPT (ALT) ≤ 2,5 veces el LSN
    13. Esperanza de vida de al menos 6 meses en la selección
    14. Los pacientes que mantienen relaciones sexuales con mujeres fértiles deben acceder a usar preservativo junto a otro método anticonceptivo eficaz. Los pacientes deben acceder a usar preservativo al mantener relaciones sexuales, incluso con una mujer embarazada. Estas limitaciones se aplicarán desde el momento en que se entregue el consentimiento informado hasta 3 semanas después de tomar la última dosis del medicamento del estudio.
    15. El paciente deberá desear y poder adherirse a todas las evaluaciones de los requisitos del protocolo
    E.4Principal exclusion criteria
    1. For mCSPC patients: any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer not specified as allowable treatment in Inclusion Criterion 6. For example, prior therapy with apalutamide or enzalutamide is prohibited as well as therapy with an investigational agent as described in Exclusion Criterion 16.
    2. For mCRPC patients:
    a) Prior treatment with abiraterone or enzalutamide is prohibited
    b) Previous chemotherapy is prohibited with exception of docetaxel treatment as specified in the inclusion criteria 6.
    3. Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start of study drug/reference product. Patients who are on a stable dose of these medications for at least 30 days at the time of starting study drug/reference product will be eligible.
    4. Therapy with estrogen within 30 days prior to the start of study drug
    5. Use of systemic glucocorticoids equivalent to >10 mg prednisone daily. Patients who have discontinued or reduced dosing to the equivalent of ≤ 10 mg prednisone daily within 14 days prior to the start of study drug are eligible
    6. Known, symptomatic metastases to the brain or central nervous system involvement (patients with asymptomatic and neurologically stable disease for the past 4 weeks will be permitted)
    7. History of adrenal gland dysfunction defined as requiring treatment for adrenal insufficiency
    8. History of other malignancy within the previous 2 years (no longer being actively treated), with the exceptions of basal cell carcinoma, non-muscle invasive bladder cancer that has been treated and is under surveillance, or other in-situ cancers with a low likelihood of recurrence
    9. Major surgery within 30 days prior to the start of study drug
    10. Known gastrointestinal disease or condition that could impair absorption inclusive of gastrocolic fistula, gastroenterostomy, biliary obstruction, cirrhosis, chronic pancreatitis or pancreatic cancer, cystic fibrosis, lactate deficiency, amyloidosis, celiac disease, Crohn’s disease, radiation enteritis, intestinal resection, and history of bariatric surgery
    11. Known history of human immunodeficiency virus or seropositive test for hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) (note: HCV patients with undetectable viral load will be eligible)
    12. Poorly controlled diabetes, defined as HbA1c > 8% within the past 12 months
    13. Uncontrolled hypertension (stage 3 hypertension or greater as defined as blood pressure greater than 179 mm Hg systolic or 109 mm Hg diastolic at enrollment)
    14. History of New York Heart Association class III or IV heart failure
    15. Serious concurrent illness, including psychiatric illness, that could interfere with study participation
    16. Receipt of another investigational agent within 4 weeks or 5 x the treatment half-life, whichever is longer, of treatment start.
    17. Known hypersensitivity or allergy to abiraterone acetate, prednisone or any excipients in the study drugs
    18. Other condition which, in the opinion of the Investigator, would preclude participation in this trial.
    1. En caso de pacientes con CPSCm:
    • Cualquier farmacoterapia o tratamiento con radiación anteriores o cirugía para el cáncer de próstata metastásico que no se incluyan como tratamiento permitido en los Criterios de inclusión 6. Por ejemplo, se prohíbe el tratamiento previo con apalutamida o enzalutamida, así como el tratamiento con un fármaco en investigación según se describe en los Criterios de exclusión 16.
    2. En caso de pacientes con CPRCm:
    • Se prohíbe el tratamiento previo con abiraterona o enzalutamida
    • Se prohíbe la quimioterapia previa salvo el tratamiento con docetaxel, tal y como se indica en los Criterios de inclusión 6.
    3. Inicio del tratamiento con bisfosfonatos o denosumab en los 30 días anteriores al inicio del medicamento del estudio/medicamento de referencia. Serán aptos los pacientes que estén en una dosis estable de estos medicamentos durante al menos 30 días en el momento del inicio del medicamento del estudio/medicamento de referencia.
    4. El tratamiento con estrógenos en los 30 días anteriores al inicio del medicamento del estudio
    5. Uso de glucocorticoides generalizados equivalentes a > 10 mg de prednisona diarios. Son aptos los pacientes que hayan interrumpido o reducido la administración del equivalente de ≤ 10 mg de prednisona diarios en los 14 días anteriores al inicio del medicamento del estudio
    6. Se permiten las metástasis conocidas y sintomáticas del cerebro o con implicación del sistema nervioso central (pacientes con enfermedad asintomática y neurológicamente estable durante las últimas 4 semanas)
    7. Antecedentes de disfunción de las glándulas suprarrenales que se define como necesidad de tratamiento para la insuficiencia suprarrenal
    8. Antecedentes de neoplasia maligna en los 2 años anteriores (que ya no se trate de forma activa), con las excepciones del carcinoma basocelular, cáncer de vejiga que no invada los tejidos musculares que haya sido tratado y se encuentre bajo vigilancia u otros cánceres in situ con una baja probabilidad de recurrencia
    9. Cirugía mayor en los 30 días anteriores al inicio del medicamento del estudio
    10. Enfermedad gastrointestinal conocida o trastorno que pudiera afectar a la absorción como la fístula gastrocólica, la gastroenterostomía, la obstrucción biliar, la cirrosis, la pancreatitis crónica o el cáncer pancreático, la fibrosis quística, la amiloidosis, la celiaquía, la enfermedad de Crohn, la colitis rádica, la resección intestinal y antecedentes de cirugía bariátrica
    11. Antecedentes conocidos del virus de la inmunodeficiencia humana o prueba seropositiva para el virus de la hepatitis C (VHC) o del antígeno de superficie de la hepatitis B (HBsAg) (nota: serán aptos los pacientes con VHC con carga viral indetectable)
    12. Diabetes mal controlada, que se define como HbA1c > 8 % en los últimos 12 meses
    13. Hipertensión no controlada (que se define como una presión arterial superior a 179 mm Hg sistólica o una 109 mm Hg diastólica en la inclusión)
    14. Antecedentes de insuficiencia cardíaca de clase III o IV según la Asociación cardiaca de Nueva York [New York Heart Association]
    15. Enfermedad simultánea grave, como la enfermedad psiquiátrica, que podría interferir con la participación en el estudio
    16. Recepción de otro fármaco en investigación en las 4 semanas previas al inicio del tratamiento o en las 5 veces la semivida del tratamiento, lo que sea más largo.
    17. Hipersensibilidad o alergia conocidas al acetato de abiraterona, la prednisona o cualquier excipiente de los medicamentos del estudio
    18. Otra enfermedad que, a juicio del investigador, imposibilitaría la participación en este ensayo
    E.5 End points
    E.5.1Primary end point(s)
    Efficacy: The primary efficacy endpoint is the comparison of the average of serum testosterone levels on days 9 and 10 between groups (TAVT-45 vs R-AA).
    Safety: Safety endpoints include incidence of treatment emergent adverse events (TEAE), and clinically relevant changes in vital signs and laboratory assessments.
    Pharmacokinetics: For a cohort of up to 8 patients randomized to TAVT-45 and participating in the serial PK sampling on Day 1 and Day 9, the following PK parameters will be determined:
    a) Area under the concentration-time curve from time zero to 12 hours post dose (AUC0-12)
    b) Maximum measured plasma concentration (Cmax)
    c) Minimum measured plasma concentration (Cmin)
    d) Time to maximum measured concentration (tmax)
    e) Accumulation ratio (Rac)
    f) Effective half-life (t½)
    Eficacia: El criterio principal de valoración de la eficacia es comparar la media de los niveles de testosterona en suero los días 9 y 10 entre los grupos (TAVT-45 frente al AA-R).
    Seguridad: entre los criterios de valoración de la seguridad, se encuentran la incidencia de acontecimientos adversos surgidos durante el tratamiento (AAST) y cambios relevantes en las constantes vitales y evaluaciones analíticas.
    Farmacocinética: para una cohorte de hasta 8 pacientes aleatorizados a TAVT-45 y que participan en las extracciones seriadas para FC el día 1 y 9, se determinarán los siguientes parámetros FC:
    a)El área bajo la curva del tiempo de concentración desde el momento 0 hasta las 12 horas después de la dosis (ABC0-12)
    b)La concentración plasmática máxima cuantificada (Cmáx.)
    c)La concentración mínima plasmática cuantificada (Cmín.)
    d)El tiempo hasta la concentración máxima cuantificada (Tmáx.)
    e)El índice de acumulación (Iac)
    f)La semivida eficaz (t½)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Average of serum testosterone levels will be compared between groups on Days 9 and 10.

    A cohort of 8 patients randomized to TAVT-45 will participate in serial PK sampling on Days 1 and 9.
    El promedio de los niveles séricos de testosterona se comparará entre los grupos en los días 9 y 10.

    Una cohorte de 8 pacientes asignados al azar a TAVT-45 participará en un muestreo de FC en serie los días 1 y 9.
    E.5.2Secondary end point(s)
    The key secondary efficacy endpoint is the PSA-50 response, defined as a decrease of ≥50% in PSA levels from baseline at any time over the 84-day post-treatment period.
    Other secondary efficacy endpoints are as follows:
    a) Serum testosterone levels at Days 28, 56 and 84
    b) PSA-50 response at Days 28, 56 and 84
    c) PSA levels at Days 28, 56 and 84
    d) Trough concentrations of abiraterone at Days 9, 28, 56 and 84
    El criterio de valoración secundario es la respuesta del PSA al 50, que se define como una disminución de ≥ 50 % de los niveles de PSA desde el inicio del estudio en cualquier momento durante el periodo posterior al tratamiento de 84 días.
    Otros criterios de valoración secundarios son los siguientes:
    a)Niveles de testosterona en suero los días 28, 56 y 84
    b)Respuesta del PSA al 50 los días 28, 56 y 84
    c)Niveles de PSA los días 28, 56 y 84
    d)Concentraciones mínimas de abiraterona los días 9, 28, 56 y 84
    E.5.2.1Timepoint(s) of evaluation of this end point
    a) Serum testosterone levels at Days 28, 56 and 84
    b) PSA-50 response at Days 28, 56 and 84
    c) PSA levels at Days 28, 56 and 84
    d) Trough concentrations of abiraterone at Days 9, 28, 56 and 84
    a)Niveles de testosterona en suero los días 28, 56 y 84
    b)Respuesta del PSA al 50 los días 28, 56 y 84
    c)Niveles de PSA los días 28, 56 y 84
    d)Concentraciones mínimas de abiraterona los días 9, 28, 56 y 84
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence Yes
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Ukraine
    United States
    France
    Germany
    Hungary
    Poland
    Spain
    Sweden
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months14
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months15
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 54
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 54
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state60
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 84
    F.4.2.2In the whole clinical trial 108
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    A follow-up phone call will be made approximately one week after the last dose for AE assessments.
    Se realizará una llamada telefónica de seguimiento aproximadamente una semana después de la última dosis para las evaluaciones de AA.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-06-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-03-11
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 07:57:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA